Advertisement

Journal of Cancer Survivorship

, Volume 12, Issue 3, pp 348–356 | Cite as

Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?

  • Ekim Ekinci
  • Salima Nathoo
  • Thushara Korattyil
  • Aisha Vadhariya
  • Hanna A. Zaghloul
  • Polly A. Niravath
  • Susan M. Abughosh
  • Meghana V. Trivedi
Review

Abstract

Purpose

Endocrine therapy reduces the risk of breast cancer recurrences and mortality in hormone receptor-positive (HR+) breast cancer survivors. However, non-adherence to treatment remains a significant problem. The aim of this study was to review current literature and ongoing trials to identify interventions employed to improve adherence to adjuvant endocrine therapy (AET) in breast cancer survivors.

Methods

We searched PubMed and the National Library of Medicine registry of clinical trials using the terms “breast cancer” and “adherence” or “compliance” and “intervention” and “medication” or “endocrine therapy” or “hormone therapy” to identify published studies as well as ongoing clinical trials.

Results

Three hundred and sixty-three studies were identified; five studies met the inclusion criteria. Most studies enrolled postmenopausal women diagnosed with early stage HR+ breast cancer. Providing educational materials was the most common intervention implemented to improve adherence to one or more aromatase inhibitors. None of the studies found a significant improvement in adherence with the intervention evaluated. Twelve clinical trials investigating various interventions, mostly based on technology, to improve AET adherence were also identified.

Conclusions

Improving adherence to AET in HR+ breast cancer survivors is an urgent medical need. While newer clinical trials are overcoming some of the limitations seen with published studies, tailored interventions led by clinicians need further investigation.

Implications for cancer survivors

Our study highlights the unmet clinical need to develop and test feasible interventions to improve AET adherence in HR+ breast cancer survivors to extend their long-term survival.

Keywords

Breast cancer Endocrine therapy Medication adherence Compliance Intervention 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.  https://doi.org/10.3322/caac.21387.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Giuliano M, Schifp R, Osborne CK, Trivedi MV. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast. 2011;20(Suppl 3):S42–9.  https://doi.org/10.1016/S0960-9776(11)70293-4.CrossRefPubMedGoogle Scholar
  3. 3.
    Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.  https://doi.org/10.1016/S0140-6736(12)61963-1.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209–19.  https://doi.org/10.1056/NEJMoa1604700.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Milata JL, Otte JL, Carpenter JS. Oral endocrine therapy nonadherence, adverse effects, decisional support, and decisional needs in women with breast cancer. Cancer Nurs. 2016:41(1):E9–E18.  https://doi.org/10.1097/NCC.0000000000000430.
  6. 6.
    Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459–78.  https://doi.org/10.1007/s10549-012-2114-5.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Cahir C, Dombrowski SU, Kelly CM, Kennedy MJ, Bennett K, Sharp L. Women’s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. Support Care Cancer. 2015;23(11):3115–30.  https://doi.org/10.1007/s00520-015-2685-x.CrossRefPubMedGoogle Scholar
  8. 8.
    Farias AJ, XL D. Association between out-of-pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among Medicare patients with breast cancer. J Clin Oncol. 2017;35(1):86–95.  https://doi.org/10.1200/JCO.2016.68.2807.CrossRefPubMedGoogle Scholar
  9. 9.
    Garreau JR, Delamelena T, Walts D, Karamlou K, Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am J Surg. 2006;192(4):496–8.  https://doi.org/10.1016/j.amjsurg.2006.06.018.CrossRefPubMedGoogle Scholar
  10. 10.
    Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–8.  https://doi.org/10.1200/JCO.2009.25.9655.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Lin C, Clark R, Tu P, Bosworth HB, Zullig LL. Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers. Breast Cancer Res Treat. 2017;165(2):247–60.  https://doi.org/10.1007/s10549-017-4317-2.CrossRefPubMedGoogle Scholar
  12. 12.
    Simon R, Latreille J, Matte C, Desjardins P, Bergeron E. Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. Can J Surg. 2014;57(1):26–32.  https://doi.org/10.1503/cjs.006211.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hadji P, Blettner M, Harbeck N, Jackisch C, Luck HJ, Windemuth-Kieselbach C, et al. The Patient’s anastrozole compliance to therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol. 2013;24(6):1505–12.  https://doi.org/10.1093/annonc/mds653.CrossRefPubMedGoogle Scholar
  14. 14.
    Markopoulos C, Neven P, Tanner M, Marty M, Kreienberg R, Atkins L, et al. Does patient education work in breast cancer? Final results from the global cariatide study. Future Oncol. 2015;11(2):205–17.  https://doi.org/10.2217/fon.14.179.CrossRefPubMedGoogle Scholar
  15. 15.
    KD Y, Zhou Y, Liu GY, Li B, He PQ, Zhang HW, et al. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Breast Cancer Res Treat. 2012;134(1):307–13.  https://doi.org/10.1007/s10549-012-2059-8.CrossRefGoogle Scholar
  16. 16.
    Ziller V, Kyvernitakis I, Knoll D, Storch A, Hars O, Hadji P. Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment—the COMPAS study. BMC Cancer. 2013;13(1):407.  https://doi.org/10.1186/1471-2407-13-407.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Wagner VL, Jing W, Boscoe FP, Schymura MJ, Roohan PJ, Gesten FC. Improving adjuvant hormone therapy use in Medicaid managed care-insured women, New York State, 2012–2014. Prev Chronic Dis. 2016;13:E120.  https://doi.org/10.5888/pcd13.160185.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Neven P, Markopoulos C, Tanner M, Marty M, Kreienberg R, Atkins L, et al. The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. Breast. 2014;23(4):393–9.  https://doi.org/10.1016/j.breast.2014.02.009.CrossRefPubMedGoogle Scholar
  19. 19.
    Nogaret J-M, Coibion M, Neven P, Soepenberg O, Graas M-P, Deschamp V, (2011) Evaluating the impact of educational material on anastrozole treatment adherence—the final results of the artemis study. Cancer Res 71 (24 Suppl):Abstract nr P3–08-02.  https://doi.org/10.1016/S0960-9776(11)70233-8
  20. 20.
    Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–37.  https://doi.org/10.1007/s10549-010-1132-4.CrossRefPubMedGoogle Scholar
  21. 21.
    Huiart L, Ferdynus C, Giorgi R. A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat. 2013;138(1):325–8.  https://doi.org/10.1007/s10549-013-2422-4.CrossRefPubMedGoogle Scholar
  22. 22.
    Cuzick J. Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer. Ann Oncol. 2015;26(12):2363–6.  https://doi.org/10.1093/annonc/mdv392.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Kesmodel SB, Goloubeva OG, Rosenblatt PY, Heiss B, Bellavance EC, Chumsri S, et al. Patient-reported adherence to adjuvant aromatase inhibitor therapy using the morisky medication adherence scale: an evaluation of predictors. Am J Clin Oncol. 2016:1.  https://doi.org/10.1097/COC.0000000000000314.
  24. 24.
    Liu Y, Malin JL, Diamant AL, Thind A, Maly RC. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat. 2013;137(3):829–36.  https://doi.org/10.1007/s10549-012-2387-8.CrossRefPubMedGoogle Scholar
  25. 25.
    Chisholm-Burns MA, Kim Lee J, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al. US pharmacists’ effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010;48(10):923–33.  https://doi.org/10.1097/MLR.0b013e3181e57962.CrossRefPubMedGoogle Scholar
  26. 26.
    Abughosh S, Wang X, Serna O, Esse T, Mann A, Masilamani S, et al. A motivational interviewing intervention by pharmacy students to improve medication adherence. J Manag Care Spec Pharm. 2017;23(5):549–60.  https://doi.org/10.18553/jmcp.2017.23.5.549.CrossRefPubMedGoogle Scholar
  27. 27.
    Albert US, Zemlin C, Hadji P, Ziller V, Kuhler B, Frank-Hahn B, et al. The impact of breast care nurses on Patients’ satisfaction, understanding of the disease, and adherence to adjuvant endocrine therapy. Breast Care (Basel). 2011;6(3):221–6.  https://doi.org/10.1159/000329006.CrossRefGoogle Scholar
  28. 28.
    Oberguggenberger AS, Sztankay M, Beer B, Schubert B, Meraner V, Oberacher H, et al. Adherence evaluation of endocrine treatment in breast cancer: methodological aspects. BMC Cancer. 2012;12(1):474.  https://doi.org/10.1186/1471-2407-12-474.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Clarke Hillyer G, Neugut AI, Crew KD, Kalinsky K, Maurer MA, Rotsides DZ, et al. Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study. J Oncol Pract. 2012;8(5):e100–4.  https://doi.org/10.1200/JOP.2011.000487.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Ekim Ekinci
    • 1
  • Salima Nathoo
    • 2
  • Thushara Korattyil
    • 2
  • Aisha Vadhariya
    • 3
  • Hanna A. Zaghloul
    • 1
  • Polly A. Niravath
    • 4
  • Susan M. Abughosh
    • 3
  • Meghana V. Trivedi
    • 2
  1. 1.Department of PharmacyHouston Methodist HospitalHoustonUSA
  2. 2.Department of Pharmacy Practice and Translational ResearchUniversity of Houston College of PharmacyHoustonUSA
  3. 3.Department of Pharmaceutical Outcomes and PolicyUniversity of Houston College of PharmacyHoustonUSA
  4. 4.Department of Internal Medicine, Hematology/Oncology DivisionHouston Methodist HospitalHoustonUSA

Personalised recommendations